Search Login Register

NAPVSIPQ peptide Summary

Description: AL-108 is a nasal systemic formulation; AL-208 is an intravenous formulation; associated with glial proteins regulated by vasoactive intestinal peptide, are shown now to provide protective intervention in a model of fetal alcohol syndrome

Also Known As: AL 108; AL 208; AL-108; AL-208; AL108 cpd Show All >>

Networked: 25 relevant articles (6 outcomes, 6 trials/studies) for this Bio-Agent

Key Diseases for which NAPVSIPQ peptide is Relevant

  1. Schizophrenia (Dementia Praecox) : 1 outcome 3 studies in 7 results
  2. Alzheimer Disease (Alzheimer's Disease) : 1 outcome 1 study in 7 results
  3. Tauopathies : 1 outcome 1 study in 5 results
  4. Anoxia (Hypoxia) : 1 outcome 1 study in 2 results
  5. Neurodegenerative Diseases (Neurodegenerative Disease) : 1 outcome in 3 results
Show All >>

Drugs Related to NAPVSIPQ peptide

  1. Glutathione Disulfide (GSSG)
  2. Kainic Acid (Kainate)
  3. Choline (Choline Chloride)
  4. N-acetylaspartate (N-acetyl aspartate)

Therapies Related to NAPVSIPQ peptide

  1. Transplants (Transplant)
  2. Therapeutics
  3. Coronary Artery Bypass (Coronary Artery Bypass Surgery)
  4. Activities of Daily Living (ADL)

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.